Spruce Biosciences, Inc. (NasdaqCM: SPRB)
Health Care · Biotechnology · US
$63.40
+22.92% today · +548.8% 1Y
Spruce Biosciences, Inc. (NasdaqCM: SPRB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $148.24M and employs 14 people.
Over the last twelve months the share price has gained 548.8%, trading between 7.00 and 240.00.
Tweenvest scores Spruce Biosciences, Inc. across four factors: quality 26/100. Its strongest factor is quality.
SPRB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $148.24M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -36.05
- Dividend yield
- —
- Beta (5Y)
- 3.34
- 52-week high
- $240.00
- 52-week low
- $7.00
- Avg volume (3M)
- —
- Shares outstanding
- 2.87M
- Employees
- 14
- Next earnings
- —
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
- ISIN
- US85209E2081
- Founded
- 2014
- Listed since
- Oct 9, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.